The Role of TBC1D4 in Exercise- and Insulin-induced Glucose Metabolism in Human Skeletal Muscle
NCT ID: NCT04170972
Last Updated: 2022-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
16 participants
INTERVENTIONAL
2017-10-17
2019-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The overall aims in the present project are to:
1. Determine whether the TBC1D4 p.Arg684Ter variant affects the regulation of glucose uptake in skeletal muscle during exercise and during physiological insulin stimulation.
2. Determine the effect of the TBC1D4 p.Arg684Ter variant for the ability of acute exercise to insulin sensitize skeletal muscle to regulate glucose metabolism.
3. Define the metabolic pathways affected by the p.Arg684Ter variant in order to identify causal factors responsible for the diabetic phenotype of Inuit carriers.
The knowledge generated will contribute to additional explanatory clues to the increased frequency of T2D in the carriers.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Interaction of Muscle Dystrophy, Glucose Metabolism and Insulin Sensitivity
NCT05052073
Skeletal Muscle Health in Children With Type 1 Diabetes
NCT04288063
Myocellular Signalling in Skeletal Muscle
NCT03203317
Exercise, Glucose Kinetics, and the Incretin Effect
NCT01607931
Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) Metabolism During Acute Hyperglycemia
NCT01178957
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Our overall aims in the present project are to:
1. Determine whether the TBC1D4 p.Arg684Ter variant affects the regulation of glucose uptake in skeletal muscle during exercise and during physiological insulin stimulation.
2. Determine the effect of the TBC1D4 p.Arg684Ter variant for the ability of acute exercise to insulin sensitize skeletal muscle to regulate glucose metabolism.
3. Define the metabolic pathways affected by the p.Arg684Ter variant in order to identify causal factors responsible for the diabetic phenotype of Inuit carriers.
The knowledge generated will contribute to additional explanatory clues to the increased frequency of T2D in the carriers.
Study population:
The Inuit Health in Transition (IHIT) study is a study of adults in West and East Greenland. The participants were selected through a stratified random sample and data were collected in 1999-2010 using clinical procedures, sampling of biological material, and questionnaires. To accomplish the goal, the investigators will carry out comprehensive metabolic phenotyping of Inuits carrying zero (n=10) or two (n=10) alleles of the TBC1D4 p.Arg684Ter variant recruited from this cohort. Based on an effect of 1.2 SD as found for plasma glucose levels during an Oral Glucose Tolerance Test (OGTT) in the previous study (6) between homozygous carriers and non-carriers of the TBCD14 variant, the investigators achieve 89% power at p=0.05 when recruiting 10 homozygous carriers and 10 non-carriers.
Methods:
Genotyping of the IHIT cohort has already been performed. Thus, the investigators can re-call study participants for the present study based on their known genotype. The investigators intend to perform highly invasive physiological studies of subjects harboring the TBC1D4 point mutation and in control subjects matched by age, gender and BMI. The participants will be nondiabetic (25-50 yrs) males recruited through the IHIT cohort register (n=4,200). The recruitment, screening and initial clinical investigations (oral glucose tolerance test and physical exercise tests, including customization to a one-legged cycling ergometer) will take place in Greenland. The most invasive part of the study, described below, will take place in Copenhagen, Denmark.
During the stay in Copenhagen participants will receive an energy-matched, standardized diet to be consumed 3 days prior to the intervention study. On the study day the participants will arrive in the laboratory after an overnight fast. Catheters will be placed in both femoral veins (V) and in one femoral artery (A). A muscle biopsy will be obtained from vastus lateralis of one leg (resting leg). The participants will then perform one legged knee extensor exercise for one hour leaving the other leg as a rested control leg. Immediately after exercise a biopsy will be obtained from the exercising leg and the participants will rest in the fasted state for 3 hours before a third set of muscle biopsies (from both legs) and one abdominal subcutaneous fat biopsy are taken. Subsequently, insulin sensitivity will be evaluated during a 2-hour physiological hyperinsulinemic euglycemic clamp. By the end of the clamp a final set of biopsies (both legs) and one abdominal subcutaneous fat biopsy will be obtained. Throughout the study day sampling of artery and venous blood/plasma samples allow estimation of substrate extraction by the two legs. Further, measures of artery blood flow by Ultrasound Doppler technique will allow a final calculation of substrate uptake/release across the two legs before exercise, during exercise and in recovery from exercise. Importantly, the ability for insulin to stimulate theses process can be evaluated in both a rested and in the prior exercised leg.
The investigators plan to carry out deep transcript profiling of muscle tissue samples and define correlations between age, sex, BMI, genetic variants, and the transcriptional profiles in order to understand the impact on gene regulation of identified metabolic genetic variants. In order to define key biochemical pathways affected by the mutated TBC1D4, the investigators will perform metabolomic analyses of the muscle biopsy samples. In order to identify putative targeted pathways affected by the mutation, the investigators will perform mass spectrometry-based interactome as well as proteomic / phosphoproteomic analyses. Based on these data and data obtained from the metabolic analyses, the investigators will be better able to identify the affected metabolic processes involved in the progression towards the diabetic phenotype of the Inuit carriers. Such pathways will in subsequent analyses be studied biochemically in more detail including additional (to phosphorylation) post translational modifications (e.g. glycosylation) as well as expression/activities of key enzymes in glucose and fat metabolism.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
1. Homozygote carriers of a p.Arg684T TBC1D4 gene-variant
2. None carriers (matched controls) of the p.Arg684T TBC1D4 gene-variant
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exercise and vivo insulin stimulation in TBC1D4 gene-variants
Acute exercise and in vivo insulin stimulation in homozygote carriers of a p.ARg684T TBC1D4 gene-variant.
Acute exercise
One hour of acute one-legged knee-extensor exercise followed by 3 hours recovery and 2 hours insulin (1.5 mU/min/kg) stimulation.
Exercise and vivo insulin stimulation in matched controls
Acute exercise and in vivo stimulation in none carriers (matched controls) of the p.Arg684T TBC1D4 gene-variant.
Acute exercise
One hour of acute one-legged knee-extensor exercise followed by 3 hours recovery and 2 hours insulin (1.5 mU/min/kg) stimulation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acute exercise
One hour of acute one-legged knee-extensor exercise followed by 3 hours recovery and 2 hours insulin (1.5 mU/min/kg) stimulation.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI between 20-35 kg/m2
Exclusion Criteria
20 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Professor Jorgen FP Wojtaszewski
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Exercise, Nutrition and Sports, Faculty of Sciences, University of Copenhagen
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Moltke I, Grarup N, Jorgensen ME, Bjerregaard P, Treebak JT, Fumagalli M, Korneliussen TS, Andersen MA, Nielsen TS, Krarup NT, Gjesing AP, Zierath JR, Linneberg A, Wu X, Sun G, Jin X, Al-Aama J, Wang J, Borch-Johnsen K, Pedersen O, Nielsen R, Albrechtsen A, Hansen T. A common Greenlandic TBC1D4 variant confers muscle insulin resistance and type 2 diabetes. Nature. 2014 Aug 14;512(7513):190-3. doi: 10.1038/nature13425. Epub 2014 Jun 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-18007316
Identifier Type: OTHER
Identifier Source: secondary_id
13057
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
5053-00095B
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
28136
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
KVUG 2016-12
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.